The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Last week could be termed as a mixed one for the biotech sectors. Big pharma earnings came in mostly positive, but the FDA rejected two NDAs, pressuring Nabriva Therapeutics PLC – ADR NBRV and Heron Therapeutics Inc HR.

The following are key catalysts for the unfolding week.

Conferences

  • 16th International Conference on Breast Pathology and Cancer Diagnosis: May 10-11 in Montreal, Canada. 
  • 2019 American Academy of Neurology annual meeting: May 4-10 in Philadelphia, Pennsylvania.
  • American Urological Association 2019 annual meeting: May 3-6 in Chicago, Illinois.
  • Hemostasis & Thrombosis Society 2019 Scientific Symposium: May 9-11 in New Orleans, Louisiana.

Clinical Trial Readouts

American Academy of Neurology Annual Meeting Presentations

Novartis AG NVS: Data from the Phase 3 SPRINT study for Zolgensma (pre-symptomatic patients with spinal muscular atrophy Types 1, 2 and 3 — as well Phase 1 data for Zolgensma in SMA Type 2 — on May 5.

Cytokinetics, Inc. CYTK: Phase 2 data for Reldesemtiv in a study dubbed FORTITUDE-ALS (amyotrophic lateral sclerosis) on May 5.

MediciNova, Inc. MNOV: additional Phase 2b data for MN-166 (progressive multiple sclerosis) on May 6.

PTC Therapeutics, Inc. PTCT and Roche Holdings AG Basel ADR RHHBY: Phase 2/3 data for RG7916 from a study dubbed SUNFISH (spinal muscular dystrophy) on May 7.

Ra Pharmaceuticals Inc RARX: already released Phase 2 data for RA101495, or zilucoplan, (myasthenia gravis) on May 7.

PTC Therapeutics: Phase 2/3 data for RG7916 from a study dubbed Firefish (spinal muscular dystrophy) on May 7.

See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

American Urological Association 2019 Annual Meeting Presentations

Urovant Sciences Ltd UROV: already released Phase 3 data for Vibegron (overactive bladder) on May 5.

Urogen Pharma Ltd URGN: already released Phase 3 data for MitoGel (urothelial carcinoma) on May 5.

Progenics Pharmaceuticals, Inc. PGNX: Phase 2/3 data for PyL (prostate cancer) on May 6.

Earnings Highlights

Monday, May 6

  • GW Pharmaceuticals PLC- ADR GWPH (after the market close)
  • Ultragenyx Pharmaceutical Inc RARE (after the market close)

Tuesday, May 7

  • Regeneron Pharmaceuticals Inc REGN (before the market open)
  • Jazz Pharmaceuticals PLC JAZZ (after the market close)

Wednesday, May 8

  • Portola Pharmaceuticals Inc PTLA (before the market open)
  • Dynavax Technologies Corporation DVAX (after the market close)

Thursday, May 9

  • Ionis Pharmaceuticals Inc IONS (before the market open)
  • Puma Biotechnology Inc PBYI (after the market close)

IPOs

Applied Therapeutics, a biotech company developing therapies for diabetic cardiomyopathy, is due to offer 4 million shares in an IPO that are likely to be priced between $14 and $16. The shares are to be listed on the Nasdaq under the ticker symbol APLT.

Axcella proposes to offer 3.57 million shares in an IPO with an estimated price range of $20-$22. The biotech developing therapies and food to treat metabolic dysregulation in the liver seeks to list its shares on the Nasdaq under the ticker symbol AXLA.

Cortexyme, which develops a novel therapy for Alzheimer's disease, is expected to offer 4.412 million shares with an estimated price range of $16-$18. The company is to list its shares on the Nasdaq under the ticker symbol CRTX.

Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, plans to offer 5 million shares to be priced between $14 and $16. The shares are to be listed on the Nasdaq under the ticker symbol MIST.

NextCure is scheduled to offer 5 million shares in an IPO, to be priced in the range of $14-$16. The shares of the cancer immunotherapy company are due to be listed on the Nasdaq under the ticker symbol NXTC.

Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: BiotechEarningsNewsPreviewsIPOsTop StoriesTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...